Skip to content

The impact of China PAR assessment and multidisciplinary team management on cardiovascular disease risk in type 2 diabetes

The impact of China PAR assessment and multidisciplinary team management on cardiovascular disease risk in type 2 diabetes

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400081572
Enrollment
Unknown
Registered
2024-03-05
Start date
2024-03-11
Completion date
Unknown
Last updated
2024-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Intervention group:1) Assess the reasons for the increase in cardiovascular risk in China-PAR: whether smoking, whether blood lipids are not up to standard, whether blood pressure is not up to standar

Sponsors

Affiliated Beijing Chaoyang Hospital of Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 90 Years

Inclusion criteria

Inclusion criteria: a) Meet the diagnostic criteria for diabetes, refer to the Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition); b) Age = 20 years, male or female; c) China-PAR risk assessment 10-year risk = 10.0% for cardiovascular disease d) Signed informed consent form to voluntarily participate in this study.

Exclusion criteria

Exclusion criteria: a) already have comorbid cardiovascular disease; b) pregnant or lactating women or women who have planned to conceive within 1 year; c) Patients with severe chronic diseases: such as severe renal insufficiency (estimated glomerular filtration rate <30 ml/min/1.73m2), liver disease (active hepatitis, decompensated chronic liver diseases such as liver cirrhosis, ascites, etc.), severe hematologic diseases or malignant tumors and other serious primary diseases; d) Patients who need to be transferred to acute treatment as judged by a doctor; e) Patients with mental disorders, cognitive dysfunction and various reasons are unable to cooperate with follow-up. f) Presence of any other condition or event that is excluded by the principal investigator or study physician in the opinion of the study physician.

Design outcomes

Primary

MeasureTime frame
Prediction for ASCVD Risk in China, China-PAR;homocysteine;creatinine;

Secondary

MeasureTime frame
Glycosylated hemoglobin;Blood pressure;Urinary albumin/creatinine ratio;blood sugar,2-hour postprandial blood glucose;Lipids (total cholesterol, triglycerides);uric acid;

Countries

China

Contacts

Public ContactQingrong Pan

Affiliated Beijing Chaoyang Hospital of Capital Medical University

panqingrongcn@163.com+86 138 1081 5209

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026